Infinity Pharmaceuticals Inc. (NASDAQ:INFI) finished Thursday with a subtraction of -$0.05 to close at $2.86, a downside of -1.72 percent. An average of 2,595,440 shares of common stock have been traded in the last five days. There was a fall of -$0.56 in the past week. The last 20 days have seen an average of 1,974,810 shares traded, while the 50-day average volume stands at 5,015,748.
INFI stock has decreased by -21.43% in the last month. The company shares reached their 1-month lowest point of $2.85 on 10/07/21. With the stock rallying to its 52-week high on 02/11/21, shares of the company touched a low of $1.04 and a high of $5.98 in 52 weeks. In spite of this, the price is down -52.17% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
259 days have passed since Infinity Pharmaceuticals Inc. (INFI) last reported insider trading activity. BVF PARTNERS L P/IL, who is 10% Owner, most recently acquired $5,848,520 shares at $4.14 per share on Jan 22.
Infinity Pharmaceuticals Inc. (INFI) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.11 for the sector. This means investors are optimistic about the stock’s future prospects. The stock’s beta is 2.17. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 135.93, the price-to-book (PB) ratio at 6.09.
The quick ratio of Infinity Pharmaceuticals Inc. for the three months ended June 29 was 9.40, and the current ratio was 9.40, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 For the recent quarter ending June 29. Infinity Pharmaceuticals Inc.’s EBITDA margin for the year ending June 29 is -2211.40%. Its gross profit as reported stood at $40.22 million compared to revenue of $1.72 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Infinity Pharmaceuticals Inc.’s return on assets was -57.10%, compared to -51.3% over the last five years. For the broader industry, ROE averaged -68.79 over the past year.
The analyst consensus anticipated Infinity Pharmaceuticals Inc.’s latest quarter earnings to come in at -$0.14 per share, but it turned out to be -$0.13, a 7.10% surprise. For the recent quarter, EBITDA amounted to -$11.13 million. Shareholders own equity worth $88.72 million.
From a technical analysis perspective, let’s take a brief look at Infinity Pharmaceuticals Inc. (INFI) price momentum. RSI 9-day as of the close on 07 October was 27.97%, suggesting the stock is oversold, with historical volatility in this time frame at 58.76%.
As of today, INFI’s price is $3.05 -16.37% or -$0.56 from its 5-day moving average. INFI is currently trading -22.28% lower than its 20-day SMA and -1.04% lower than its 100-day SMA. However, the stock’s current price level is +16.73% above the SMA50 and +35.55% above the SMA200.
The stochastic %K and %D were 1.69% and 6.46%, respectively, and the average true range (ATR) was 0.22. With the 14-day stochastic at 1.63% and the average true range at 0.23, the RSI (14) stands at 36.08%. The stock has reached -0.35 on the 9-day MACD Oscillator while the 14-day reading was at -0.47.
JP Morgan upgraded Infinity Pharmaceuticals Inc. (NASDAQ: INFI) to a an Overweight rating in its most recent analyst report. Previously, the stock was rated as a a Neutral.The consensus rating for Infinity Pharmaceuticals Inc. (INFI) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell INFI, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 7 others rate it as a “buy”.
What is INFI’s price target for the next 12 months?
Analysts predict a range of price targets between $4.00 and $14.00, with a median target of $9.00. Taking a look at these predictions, the average price target given by analysts for Infinity Pharmaceuticals Inc. (INFI) stock is $9.29.